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Abstract
Background:  The atheroprotective effects of systemic delivery of either apolipoprotein A-I
(wtApoA-I) or the naturally occurring mutant ApoA-I Milano (ApoA-IM) have been established in
animal and human trials, but direct comparison studies evaluating the phenotype of ApoA-I or
ApoAI-Milano knock-in mice or bone marrow transplantated animals with selectively ApoA-I or
ApoAI-Milano transduced macrophages give conflicting results regarding the superior performance
of either one. We therefore sought to compare the two forms of apoA-I using liver-directed
somatic gene transfer in hypercholesterinemic mice – a model which is most adequately mimicking
the clinical setting.
Methods and results: Vectors based on AAV serotype 8 (AAV2.8) encoding wtApoA-I, ApoA-
IM or green fluorescent protein (GFP) as control were constructed. LDL receptor deficient mice
were fed a Western Diet. After 8 weeks the AAV vectors were injected, and 6 weeks later
atherosclerotic lesion size was determined by aortic en face analysis. Expression of wtApoA-I
reduced progression of atherosclerosis by 32% compared with control (p = 0.02) and of ApoA-IM
by 24% (p = 0.04). There was no significant difference between the two forms of ApoA-I in
inhibiting atherosclerosis progression.
Conclusion:  Liver-directed AAV2.8-mediated gene transfer of wtApoA-I and ApoA-IM each
significantly reduced atherosclerosis progression to a similar extent.
Background
Apolipoprotein A-I (wtApoA-I) is the primary protein
component of high density lipoproteins (HDL) [1] and
like HDL cholesterol is inversely associated with athero-
sclerotic cardiovascular disease. Transgenic overexpres-
sion of wtApoA-I in liver substantially reduces progression
of atherosclerosis in mice [2,3] and rabbits [4]. Further-
more, somatic gene transfer of wtApoA-I to liver using
adenoviral vectors reduces progression [5,6] and induces
regression [7] of atherosclerosis.
ApoA-I Milano (ApoA-IM) is a rare, naturally-occurring
Arg173Cys point mutation in ApoA-I. Heterozygosity for
ApoA-IM is associated with very low levels of HDL-C but
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no apparent increased risk of CHD [8]. ApoA-IM has been
studied extensively with regard to effects on atherosclero-
sis, including infusion and genetic expression in animals
[8,9] and even in a clinical trial of repeated intravenous
infusion of an a ApoA-IM /phospholipid complexes in
patients with CHD [10]. It has been suggested that ApoA-
IM may be a gain-of-function mutation. Indeed, a recent
study perfomed by Shan did show a superior atheropro-
tective effect of ApoA-IM compared to wtApoA-I trans-
duced macrophages after bone marrow transplantation
into ApoAI/ApoE double knock-out mice [11]. In contrast
to that, female ApoA-IM knock-in animals are character-
ized by higher serum cholesterol levels and the develop-
ment of larger atherosclerotic lesions compared to ApoA-
I knock-in mice [12]. Due to the major differences in out-
come of these studies and the lack of resemblance to the
clinical setting in which patients with normal ApoA-I lev-
els are treated with a systemically delivered ApoA-I or
ApoA-IM mimetic compound, we wanted to elucidate the
effects of wtApoA-I or ApoA-IM overexpression in a mouse
model susceptible for atherosclerosis.
Adeno-associated viral (AAV) vectors have been shown to
be capable of stable gene transfer and hepatic expression
[13,14]. First-generation AAV vectors have been used to
express wtApoA-I in mouse liver [15] and ApoA-IM in
mouse muscle [16], but in both cases the levels of expres-
sion and plasma concentrations were extremely low com-
pared with normal ApoA-I levels in mice and humans.
Much greater expression can be obtained using vectors
based on AAV serotype 8 [17]. A comparative study of
AAV serotypes delivered intraportally showed that AAV8-
based vectors achieved the highest levels of hepatic trans-
gene expression and ranged from 16 to 110 times greater
than that of AAV2; gene transfer from AAV2/7 was inter-
mediate [18].
Therefore, in the current study we used AAV8-based vec-
tors to express wtApoA-I and ApoA-IM in LDLreceptor defi-
cient mice to test whether AAV-based overexpression of
ApoA-I would reduce progression of atherosclerosis in
this model and whether wtApoA-I and ApoA-IM differed in
their effects on atherosclerosis.
Methods
Vectors
Transgenes were human wtApoA-I and human apoA-I-
Milano for the treatment groups and green fluorescent
protein (eGFP) for the control group. The human ApoA-I-
Milano gene was cloned via site directed mutagenesis of
the wtApoA-I plasmid by PCR. Correct cloning was con-
firmed by sequencing and restriction digests. To produce
AAV vectors encapsidated in an AAV8 capsid (AAV2.8), a
pseudotyping strategy was performed as reported [18,19].
Vectors were purified using a standard cesium sedimenta-
tion method and titers were determined via TaqMan anal-
ysis using probes and primers targeting the BGH poly(A+)
region of the vectors.
Animal studies
LDL receptor deficient mice on C57BL/6 background
(LDLR-/- mice) were purchased from the Jackson Labora-
tory (Bar Harbor, ME, USA) and maintained as a breeding
colony. Mice were given unrestricted access to water. Male
mice were put on western diet (0.15% cholesterol, 21%
butterfat, DYETS, PA) for 8 weeks. After this time period,
one group of animals was killed to determine the amount
of atherosclerosis development at baseline. The remaining
animals were randomly divided into 3 groups and
injected intraportally with AAV2.8-TBG-wtApoA-I,
AAV2.8-TBG-ApoA-IM, or AAV2.8-TBG-GFP at a dose 1 ×
10e12 genome copies/mouse, tail vein injection. Animals
remained on a western diet for 6 weeks thereafter and
were then sacrificed. From all animals blood was obtained
at least two times before and at designated time-points
after gene transfer. At time of necropsy livers, hearts and
aortas were harvested for further analysis. All studies were
approved by the Institutional Animal Care and Use Com-
mittee of the Wistar Institute and the University of Penn-
sylvania.
Serum analysis
Blood samples were obtained from the retro-orbital
plexus. For selected time points serum lipoproteins were
separated by Fast Performance Liquid Chromatography
(FPLC). The amount of plasma lipoproteins in the serum
or the FPLC fractions was detected using an automated
clinical chemistry analyzer (Alpha Wassermann, USA) or
a manual assay according to the manufacturers instruc-
tion (Wako, USA). FPLC fractions #3;-#10 are correspond-
ing to VLDL, #11;-#24 to IDL/LDL, and #25;-#40 to HDL.
Western Blot
Serum (0.25 µl/well) or FPLC fractions (5 µl/well) were
resolved on a 10% BisTris gel and transferred to PVDF
membrane (Invitrogen, Carlsbad, California, USA). A pol-
yclonal goat anti-human ApoA-I antibody (K45252G,
Biodesign, Maine, USA) was used as primary antibody.
Blots were developed using chemiluminescence.
RealTime PCR
Gene expression was analyzed in liver samples using the
"Assay on demand" System for murine and human apoli-
poprotein A-I from Applied Biosystems (Foster City, CA,
USA) according to the manufacturer's instructions.
Histological analysis
For the quantification of the aortic plaques, the mouse
aorta was carefully harvested and stained with Sudan IVCardiovascular Diabetology 2007, 6:15 http://www.cardiab.com/content/6/1/15
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(Sigma, Germany). Plaque size was determined using
Phase 3 Imaging System (Media Cybernetics).
Statistical analysis
For the statistical analysis a T-Test was performed. Data
are described as Mean ± standard error of the mean
(SEM). Differences with a p-value less than 0.5 were con-
sidered significant.
Results
ApoA-I expression and plasma lipids
Two weeks after injection, plasma levels of human ApoA-
I were about 20 mg/dL in mice expressing wild-type
wtApoA-I and about 30 mg/dl in mice expressing ApoA-
IM, and they increased during the 6 weeks (Fig 1a and
Table 1). Non-reduced SDS-PAGE of plasma revealed the
presence of ApoA-I dimers in the ApoA-IM but not in the
wtApoA-I treated or control groups (Fig 1b). At six weeks,
upon necropsy, the hepatic mRNA abundance in the
wtApoA-I and ApoA-IM groups were not significantly dif-
ferent (Fig 1c).
Expression of wild-type wtApoA-I or ApoA-IM had no sig-
nificant effect on plasma total cholesterol, triglycerides, or
phospholipids, but did reduce HDL-C levels (Table 1).
Lipoprotein fractionation revealed no significant differ-
ences in the distribution of cholesterol among the three
groups (Fig 2a). Western Blot analysis of the HDL frac-
tions revealed both monomer and dimer of ApoA-IM and
only monomer of wtApoA-I, as expected and showed no
significantly different distribution pattern of the ApoA-I
protein between the ApoA-IM and the wtApoA-I treated
animals (Fig 2b).
Atherosclerosis progression
All three groups of mice injected with vector and followed
for an additional 6 weeks had more atherosclerosis than
mice analyzed at baseline (Fig. 3b). Animals injected with
AAV8-wtApoA-I had 32% less aortic atherosclerosis than
control animals (p = 0.02), whereas animals injected with
AAV8-ApoA-IM had 24% less atherosclerosis than controls
(p = 0.04) (Figs 3a and 3b). There was no statistical differ-
ence between the wild-type and ApoA-IM groups.
Discussion
In this manuscript, we report two new findings. First, we
demonstrate using an AAV8-based vector to express wild-
type human ApoA-I in the livers of atherosclerosis-prone
mice that expression of ApoA-I is of sufficient extent and
duration to significantly slow the progression of athero-
sclerosis. Second, in a direct comparison, we demonstrate
that while expression of ApoA-IM also significantly slowed
progression of atherosclerosis compared with controls, it
did not differ significantly from wtApoA-I with regard to
effects on atherosclerosis.
While somatic gene transfer of wtApoA-I to liver using
adenoviral vectors has been shown to reduce progression
[5,6] and even induce regression [7] of atherosclerosis in
mice, expression is transient and associated with substan-
tial inflammation. In contrast, expression of wtApoA-I
using these AAV8-based vectors was stable for 6 weeks and
was associated with no increases in liver transaminases
(data not shown). Importantly, expression and plasma
levels of wtApoA-I were substantially higher than were
seen using first generation AAV vectors [15]. This allowed
us to reliably compare two different forms of ApoA-I,
wild-type and Milano, with regard to their effects on
atherosclerosis.
Previous studies have already evaluated the effects of bone
marrow transplantations with retrovirally ApoA-I or
ApoA-IM  transduced macrophages into hyperlipidemic
ApoA-I/ApoE double knock out mice. In this experimen-
tal setting selective overexpression of wtApoA-I or ApoA-
IM in macrophages significantly decreased aortic athero-
sclerosis as well as atherosclerotic plaque macrophage
immunoreactivity, effects which were more pronounced
with ApoA-IM compared to wtApoA-I [11]. In a second
study the phenotype of ApoA-I or ApoA-IM knock-in mice
on an atherosclerosis prone ApoB/ApoAII background
was analyzed [12] with the finding of a less favorable lipid
profile and a more pronounced atherosclerosis develop-
ment in female ApoA-IM knock-in mice. These results pro-
vided by Shah and Rubin's groups provide cardinal
differences in the comparison of wtApoA-I or ApoA-IM,
which might be due to the selection of animal models.
Nevertheless, both studies lack resemblance to the clinical
setting in which patients with normal ApoA-I levels are
treated with a systemically delivered ApoA-I or ApoA-IM
mimetic compound. In our current report, we demon-
strate that AAV8-mediated gene transfer with hepatic
expression of wtApoA-I or ApoA-IM results in plasma lev-
els of ApoA-I that are sufficient to significantly slow the
development of atherosclerosis in mice. Interestingly we
find that both forms, wtApoA-I and ApoA-IM, to be similar
effective in their ability to retard atherosclerosis develop-
ment in LDLr knockout mice.
Atheroprotection did occur despite a reduction in serum
HDL levels in both treatment groups. This mimics the
human situation, in which ApoA-I Milano carriers have
reduced levels of HDL cholesterol, which paradoxically is
associated with atheroprotection.
The exact mechanism for the ApoA-I Milano induced
decrease in HDL levels is not completely elucidated yet
and the fact, that so far only heterozygotes for the muta-
tion have been identified, who are producing wild-type
and mutated ApoA-I, is making the answer more difficult.Cardiovascular Diabetology 2007, 6:15 http://www.cardiab.com/content/6/1/15
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a) Serum levels of human apoA-I as evaluated at designated time points over the course of the study Figure 1
a) Serum levels of human apoA-I as evaluated at designated time points over the course of the study. There was no significant 
cross-reaction between mouse and the human apoA-I. Human apoA-I levels were increased in the groups treated with the 
human wtApoA-I (* p < 0.01) and ApoA-IM (# p < 0.01) compared to control b) Western Blots of mouse serum obtained 14 
days after gene transfer under reduced and non-reduced conditions. In contrast to animals treated with the wtApoA-I or GFP-
control vector there was under non-reduced conditions an additional band detected in the samples of the ApoA-IM animals 
corresponding with an apoA-I dimer. c) RealTime PCR from liver RNA for murine and human ApoA-I mRNA levels. There was 
no significant difference in expression levels of murine ApoA-I. Human ApoA-I was only detected in treated animals without a 
difference in mRNA levels between animals receiving the wild type or the mutant ApoA-I.
Figure 1
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One of the hypotheses is that HDL-bound ApoA-I Milano
leads to a faster catabolism of the HDL particles. This
increase in cholesterol efflux from HDL-ApoA-I Milano
particles was proven in ApoA-I Milano transgenic mice,
which also display a decrease in HDL levels [20,21].
The lipid data obtained in our animal model are therefore
highly consistent with the human phenotype and the
results from the transgenic animals. In our model HDL
levels did also slightly decrease in those animals treated
with wtApoA-I, even though to a lesser extent than in
those treated with ApoA-I Milano. Hepatic mRNA levels
of murine ApoA-I did not differ between control and
wtApoA-I or ApoA-I Milano treated animals in our study,
therefore a down-regulation of the endogenous gene due
to the AAV gene transfer is unlikely.
It is clear that the plasma HDL concentration itself is nei-
ther a surrogate for its functionality nor the kinetics of
reverse cholesterol transport [22]. Since the main determi-
nant of HDL levels is its clearance and the metabolism of
the mature HDL particle is highly dependent on its com-
position, it is imaginable that also the wtApoA-I gene
transfer did led to the production of HDL particles with a
more favorable metabolism.
Another assumption is, that essentially replacing murine
apoA-I with human apoA-I in these studies resulted in a
more functional HDL that inhibited atherosclerosis, and
that wild-type and Milano did not differ in this effect.
Indeed, there is substantial interest in the structural differ-
ences between human and murine apoA-I and it is plausi-
ble that they would differ in their anti-atherogenic effects.
Further experiments have to be performed to further elu-
cidate this phenomenon.
In conclusion, these results support the concept of using
second generation AAV8-based vectors to achieve hepatic
gene transfer and expression of transgenes that encode
abundant plasma proteins (such as ApoA-I) for studies in
animals. They also suggest that systemic wtApoA-I overex-
pression is as effective as ApoA-IM  overexpression in
reducing atherosclerosis progression in susceptible mice.
Finally, they suggest that AAV8-mediated gene transfer of
either wtApoA-I or ApoA-IM could be considered as an
experimental clinical approach for the treatment of
atherosclerosis.
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Table 1: Lipid profiles 6 weeks after gene transfer (14 weeks on Western Diet).
control ApoA-I Milano wtApoA-I
Cholesterol [mg/dl] 1843 ± 121 1844 ± 107 1873 ± 143
Triglycerides [mg/dl] 480 ± 80 617 ± 63 531 ± 88
HDL [mg/dl] 319 ± 15 248 ± 19 ** 272 ± 17 *
Phospholipids [mg/dl] 1035 ± 64 1002 ± 63 992 ± 66
Human ApoA-I [mg/dl] 7.5 ± 0.4 68 ± 4.8 **,# 51 ± 4,3 **
** p < 0.01 vs. control, * p < 0.05 vs. control, # p < 0.05 vs. ApoA-ICardiovascular Diabetology 2007, 6:15 http://www.cardiab.com/content/6/1/15
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Cholesterol and triglyceride analysis of FPLC fractions of serum samples 14 days after viral gene transfer Figure 2
Cholesterol and triglyceride analysis of FPLC fractions of serum samples 14 days after viral gene transfer. Western blot analysis 
for human apoA-I in the HDL fractions is shown below the cholesterol tracing.
0
10
20
30
40
50
60
70
01 02 03 04 05 0
c
h
o
l
e
s
t
e
r
o
l
 
[
m
g
/
d
l
]
ApoA1 M
ApoA1
control
Dimer
Monomer
Monomer
0
10
20
30
40
50
60
70
0
10
20
30
40
50
60
70
01 02 03 04 05 0
ApoA1 M
ApoA1
control
ApoA1-M 
Monomer
ApoA1
0
10
20
30
40
50
60
01 0 2 0 3 0 4 0 5 0
T
r
i
g
l
y
c
e
r
i
d
e
s
 
[
m
g
/
d
l
]
ApoA1 M
ApoA1
control
a.
b.
VLDL LDL HDLCardiovascular Diabetology 2007, 6:15 http://www.cardiab.com/content/6/1/15
Page 7 of 8
(page number not for citation purposes)
a) Representative aortas stained with Sudan IV Figure 3
a) Representative aortas stained with Sudan IV. b) Determination of total aortic plaque area as evaluated with en face analysis. 
Compared with the control group, there was significantly less atherosclerosis animals treated with wtApoA-I (*p < 0.02) and 
ApoA-IM (# p < 0.04) but no significant difference between the wtApoA-I and ApoA-IM groups.
Figure 3
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